SCHEDULE: Accelmed Stake in STRATA Skin Sciences Shifts Post-Offering

Accelmed Partners' beneficial ownership in STRATA Skin Sciences adjusted to 27.4% following a registered direct offering that increased outstanding shares.

Summary

• Accelmed Partners, L.P. and its affiliates, including Uri Geiger, beneficially own 1,441,835 shares of STRATA Skin Sciences common stock.
• This beneficial ownership represents 27.4% of the total outstanding common stock of STRATA Skin Sciences.
• The change in percentage of class is a result of STRATA Skin Sciences' registered direct offering, which closed on September 4, 2025.
• The offering involved the issuance of 1,097,547 new shares of common stock to third-party investors.
• Following the offering, the total number of common stock shares outstanding for STRATA Skin Sciences increased to 5,268,708.

Sentiment

Score: 6

Explanation: The filing reports a factual change in beneficial ownership percentage for Accelmed Partners due to STRATA Skin Sciences' successful completion of a registered direct offering. While Accelmed's percentage ownership decreased, the offering itself represents a successful capital raise for STRATA.

Positives

• STRATA Skin Sciences successfully completed a registered direct offering, issuing 1,097,547 shares, indicating a successful capital raise for the company.

Negatives

• Accelmed Partners' percentage of beneficial ownership in STRATA Skin Sciences decreased to 27.4% due to the dilution from the issuance of new shares in the offering.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders (STRATA): Existing shareholders, including Accelmed Partners, experienced dilution of their percentage ownership due to the issuance of new shares in the offering.
• STRATA Skin Sciences: The company successfully raised capital through the direct offering, which can be used for general corporate purposes, operations, or strategic initiatives.

Key Dates

Recommendation

The filing is an amendment to a Schedule 13D, primarily reporting a factual change in beneficial ownership percentage for Accelmed Partners due to a registered direct offering by STRATA Skin Sciences. While the offering successfully raised capital for STRATA, it also resulted in dilution for existing shareholders, including Accelmed. Without further information on STRATA's financial performance, strategic plans, or the specific use of proceeds from the offering, a 'hold' recommendation is appropriate as this filing alone does not present a clear catalyst for a strong buy or sell decision.

Keywords

STRATA Skin Sciences, Accelmed Partners, Schedule 13D, Beneficial Ownership, Registered Direct Offering, Common Stock, Equity Stake, Uri Geiger